- $172.59m
- $177.79m
- $56.13m
- 47
- 22
- 95
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 61.42 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.6 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.85% | ||
| Return on Equity | -72.6% | ||
| Operating Margin | -22.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 44.53 | 63.13 | 73.67 | 79.18 | 56.13 | 71.45 | 110.66 | 9.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +45.74 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 18th, 2014
- Public Since
- November 12th, 2021
- No. of Shareholders
- 44
- No. of Employees
- 41
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 23,104,437
- Address
- 9237 E Via De Ventura Blvd., SCOTTSDALE, 85258
- Web
- https://journeymedicalcorp.com/
- Phone
- +1 4804346670
- Contact
- Jaclyn Jaffe
- Auditors
- KPMG LLP
Upcoming Events for DERM
Journey Medical Corp Annual Shareholders Meeting
Journey Medical Corp Annual Shareholders Meeting
Q2 2025 Journey Medical Corp Earnings Release
Similar to DERM
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Journey Medical share price?
As of Today at 21:27 UTC, shares in Journey Medical are trading at $7.47. This share price information is delayed by 15 minutes.
How has the Journey Medical share price performed this year?
Shares in Journey Medical last closed at $7.47 and the price had moved by +113.43% over the past 365 days. In terms of relative price strength the Journey Medical share price has outperformed the S&P500 Index by +97% over the past year.
What are the analyst and broker recommendations for Journey Medical?
The overall consensus recommendation for Journey Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Journey Medical dividend yield?
Journey Medical does not currently pay a dividend.
Does Journey Medical pay a dividend?
Journey Medical does not currently pay a dividend.
When does Journey Medical next pay dividends?
Journey Medical does not currently pay a dividend.
How do I buy Journey Medical shares?
To buy shares in Journey Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Journey Medical?
As of the previous close price of $7.47, shares in Journey Medical had a market capitalisation of $172.59m.
Where are Journey Medical shares listed?
Here are the trading details for Journey Medical:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DERM
What kind of share is Journey Medical?
Based on an overall assessment of its quality, value and momentum Journey Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Journey Medical share price forecast for 2025?
The analyst consensus target price for shares in Journey Medical is $9.88. That is 32.26% above the last closing price of $7.47.
Analysts covering Journey Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.28 for the next financial year.
Find out moreWhat is the trend in the Journey Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Journey Medical. Over the past six months, its share price has outperformed the S&P500 Index by +36.69%.
As of the last closing price of $7.47, shares in Journey Medical were trading +40.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Journey Medical PE Ratio?
The Journey Medical PE ratio based on its reported earnings over the past 12 months is 61.42. The shares last closed at $7.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Journey Medical?
We do not have data on Journey Medical's directors